Novaphergan (Promethazine Hydrochloride)

Promethazine, the active ingredient in Novaphergan, is a first‑generation H1 antagonist presented as a topical formulation for cutaneous use. It is employed to relieve itching and skin inflammation associated with allergic conditions.

GNH USA supplies Novaphergan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novaphergan, a first‑generation antihistamine, acts on histamine‑mediated skin reactions. - Pruritus: reduces itching and discomfort caused by allergic skin disorders. - Allergic dermatitis: alleviates inflammation and redness in contact or atopic dermatitis. - Urticaria: helps control wheal formation and itching in hives.

Adverse reactions may occur with topical use of promethazine.

Common Side Effects: - Drowsiness: mild to moderate sedation at the application site. - Dry mouth: reduced salivation leading to a feeling of thirst. - Blurred vision: temporary visual disturbance. - Constipation: slowed gastrointestinal motility. - Urinary retention: difficulty initiating urination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Blood dyscrasias: rare hematologic abnormalities such as agranulocytosis. - Seizures: occasional central nervous system excitation. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.

When using Novaphergan, consider the following safety measures. - Pediatric use: limit application in children due to increased risk of sedation. - Glaucoma: avoid in patients with narrow‑angle glaucoma because of anticholinergic effects. - CNS depression: caution when combined with other sedatives or alcohol. - Hepatic impairment: monitor liver function as metabolism occurs primarily in the liver. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Promethazine may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Central nervous system depressants (e.g., benzodiazepines): additive sedation. - Other anticholinergic agents: heightened anticholinergic burden.

Moderate Interactions (Monitor Closely): - Opioid analgesics: may enhance respiratory depression. - Tricyclic antidepressants: increased anticholinergic side effects. - Carbamazepine: may reduce promethazine plasma levels.